Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 6 of 16
Jul 21, 2026Tempus AI is making headlines with its $1.5 billion agreement to acquire Personalis, fusing two longstanding partners in the high-stakes arena of minimal residual disease (MRD) diagnostics. This move highlights the intensifying demand for non-invasive cancer detection tools and underscores broader shifts in how cancer patients will be diagnosed and monitored.
Jul 20, 2026Harnessing advances in cell therapy, Kyverna Therapeutics is approaching an historic FDA submission for a CAR T therapy in autoimmune disease. The company's 'pipeline-in-a-product' strategy highlights both innovation and the ongoing evolution of cell therapies in treating complex immunologic disorders.
Jul 17, 2026Merck’s newly approved oral PCSK9 inhibitor marks a landmark in the treatment of high cholesterol, promising greater accessibility for patients. The development sees Merck outpace rival firms in delivering a pill-based alternative, which could reshape cholesterol management worldwide.
Jul 16, 2026Eli Lilly’s $2.8 billion upfront acquisition of AtaiBeckley highlights mainstream industry interest in psychedelic-based therapies for mental illness. This move significantly broadens Lilly's neuroscience portfolio and signals potential shifts in how major pharmaceutical companies approach mental health treatment innovation.
Jul 16, 2026Celcuity’s landmark FDA approval of Revtorpyk for advanced breast cancer marks the introduction of a new drug class in oncology. The medicine is approved for cases not characterized by a specific mutation and is aiming to fill a critical gap for many patients facing limited treatment options.
Jul 15, 2026A new landmark study attempts to decipher the mechanistic link between Epstein-Barr viral infection and the aberrant immune activity characterizing multiple sclerosis. This breakthrough advances our understanding of autoimmune triggers and could shape future research and therapeutic strategies.
Jul 14, 2026Spero Therapeutics has committed over $1 billion to secure development rights for Innovent’s SP001, an investigational anti-CD40L antibody aimed at IgG4-related disease. With a Phase 2 study on the horizon for 2027, this deal highlights both the enduring value of innovative autoimmune therapies and the ongoing appetite for high-stakes biotech partnerships.
Jul 14, 2026GSK’s antibody drug Jemperli showed success in a decisive Phase 2 study for patients with a rare rectal cancer subtype. This positive outcome paves the way for the company’s anticipated FDA submission and may influence future strategies for accelerated oncology drug review in the U.S.
Jul 13, 2026While mainstream discussion centers on only two obesity-associated gene variants, hundreds of genetic factors shape individual risk. This post delves into why oversimplifying genetic causality in obesity distorts scientific understanding, clinical approaches, and public policy—and why a more nuanced view is vital for innovation.
Jul 13, 2026The scientific community continues to make strides in understanding and treating Alzheimer’s disease. At AAIC 2026, tau protein research and blood-brain barrier breakthroughs are at the forefront, potentially reframing future therapeutic pathways. This in-depth analysis contextualizes the significance of these scientific advancements.
Jul 10, 2026A new funding push by ARPA-H funnels $160 million toward custom gene editing for rare diseases, involving seven research labs and potentially catalyzing breakthroughs across the biotech sector. While the project faced delays due to administrative transitions, this large-scale investment signals robust government backing for next-generation therapeutic technologies and could reshape the landscape for treating ultra-rare conditions.
Jul 9, 2026In the wake of FDA’s policy evolution away from exclusive reliance on animal testing, startups and established companies alike are racing to refine preclinical drug testing methods. While technologies like organoids and organ-on-a-chip platforms are gaining popularity, a new push for whole-organ testing by a Connecticut-based startup may reshape industry standards for evaluating human drug response.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.